We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Earnings Estimates Moving Higher for Medifast (MED): Time to Buy?
Read MoreHide Full Article
Medifast, Inc. (MED - Free Report) is a leading manufacturer and distributor of clinically proven, healthy living products and programs that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MED’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Medifast could be a solid choice for investors.
Current Quarter Estimates for MED
In the past 30 days, one estimate have gone higher for Medifast while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing 61 cents a share 30 days ago, to 86 cents today, a move of 41%.
Current Year Estimates for MED
Meanwhile, Medifast’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $2.60 a share 30 days ago, to $3.25 today, an increase of 25%.
The stock has also started to move higher lately, adding 36.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Earnings Estimates Moving Higher for Medifast (MED): Time to Buy?
Medifast, Inc. (MED - Free Report) is a leading manufacturer and distributor of clinically proven, healthy living products and programs that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MED’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Medifast could be a solid choice for investors.
Current Quarter Estimates for MED
In the past 30 days, one estimate have gone higher for Medifast while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing 61 cents a share 30 days ago, to 86 cents today, a move of 41%.
Current Year Estimates for MED
Meanwhile, Medifast’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $2.60 a share 30 days ago, to $3.25 today, an increase of 25%.
MEDIFAST INC Price and Consensus
MEDIFAST INC Price and Consensus | MEDIFAST INC Quote
Bottom Line
The stock has also started to move higher lately, adding 36.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>